Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Chugai’s GYM329 may offset muscle loss linked to obesity drugs like orforglipron ... Also Read: Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...

Eli Lilly & Co. sees 60% sales increase for weight-loss drug Mounjaro in India, tapping into growing market demand.

Sales of Eli Lilly ... diabetes drug was available in the country following its commercial rollout in late March, Bloomberg News reported on Saturday. Citing data from India-based market analysis ...